Shah et al., 2002). A better understanding of the regula-Kristen M. Smith, Rinat Yacobi, tion of Bcr-Abl catalytic activity is essential for future and Richard A. Van Etten, 1, * rational drug development. The Center for Blood Research and The N terminus of Bcr contains a region predicted to Department of Medicine form an amphipathic ␣ helix that tetramerizes as a pep-Harvard Medical School tide in vitro (McWhirter et al., 1993). The crystal structure Boston, Massachusetts 02115 of the Bcr coiled coil has recently been solved (Zhao et al., 2002), and the monomer forms a left-handed ␣ helix characterized by a heptad repeat with apolar residues Summary in the first (a) and fourth (d) positions of the repeat. Two monomers associate in an antiparallel dimer that stacks Bcr-Abl is a dysregulated tyrosine kinase whose to form a tetramer, consistent with experimental obmechanism of activation is unclear. Here, we demonservations. Deletion of the initial 63 amino acids of Bcr strate that, like c-Abl, Bcr-Abl is negatively regulated or insertion of proline-containing peptides into the through its SH3 domain. Kinase activity, transforma-␣-helical domain generates Bcr-Abl fusion proteins with tion, and leukemogenesis by Bcr-Abl are greatly imdecreased in vivo tyrosine kinase activity and impaired paired by mutations of the Bcr coiled-coil domain that induction of anchorage-independent growth in Rat1 fidisrupt oligomerization, but restored by an SH3 point broblasts (McWhirter et al., 1993). These results suggest mutation that blocks ligand binding or a complementhat oligomerization of Bcr-Abl increases tyrosine kinase tary mutation at the intramolecular SH3 binding site activity and may also mediate other events, such as defined in c-Abl. Phosphorylation of tyrosines in the crosslinking of F-actin (McWhirter and Wang, 1993), activation loop of the catalytic domain and the linker which may be essential for transformation and leukemobetween the SH2 and catalytic domains (SH2-CD linker) genesis. is dependent on oligomerization and required for leu-By analogy to receptor tyrosine kinases that are dikemogenesis. These results suggest that Bcr-Abl has merized by extracellular ligands (Schlessinger, 2000), a a monomeric, unphosphorylated state with the SH3 simple model suggests that fusion of Bcr activates the domain engaged intramolecularly to Pro1124 in the Abl kinase by dimerization-induced intermolecular auto-SH2-CD linker, the form that is sensitive to the inhibitor phosphorylation. Fibroblast transformation by Bcr-Abl imatinib (STI-571). The sole function of the coiled-coil lacking the coiled-coil domain can be restored by redomain is to disrupt the autoinhibited conformation placement with the leucine zipper domain from GCN4 through oligomerization and intermolecular autophos-(McWhirter and Wang, 1997) or a conditional oligomerphorylation. ization motif (K.M.S. and R.A.V., unpublished data), demonstrating that the transforming properties of Bcr-Introduction Abl, like c-Abl (Smith and Van Etten, 2001), can be activated by dimerization. Transformation by Bcr-Abl lack-As the direct cause of chronic myeloid leukemia (CML), ing the coiled-coil domain can also be partially restored Bcr-Abl is a key therapeutic target. While the catalytic by deletion of the SH3 domain (Maru et al., 1996). Howactivity of the c-Abl tyrosine kinase is very tightly reguever, there is no direct evidence that oligomerization is lated in vivo (Pendergast, 2002), the chimeric Bcr-Abl the critical function of Bcr sequences in transformation protein has constitutively increased tyrosine kinase acand leukemogenesis by Bcr-Abl, and mechanistic roles tivity (Konopka and Witte, 1985). c-Abl is regulated for autophosphorylation and the SH3 domain in Bcr-Abl through a complex mechanism that includes intramoleccatalytic and biological activity have not been defined. ular inhibition via the SH3 (Barila and Superti-Furga, To clarify the role of the Bcr coiled-coil domain in 1998; Brasher et al., 2001; Van Etten et al., 1995) and regulating the catalytic and oncogenic activity of p210 N-terminal domains (Pluk et al., 2002), regulatory tyro-Bcr-Abl, we generated several novel Bcr coiled-coil musine phosphorylation (Brasher and Van Etten, 2000; tations that are predicted to abrogate oligomerization, Dorey et al., 2001), and binding of cellular inhibitors as well as complementary point mutations in the SH3 (Pendergast et al., 1991a; Wen and Van Etten, 1997).
. p210, and p230). To investigate the role of the Bcr coiledcoil domain in regulating catalytic activity, cellular transformation, and leukemogenesis by p210 Bcr-Abl, we Bcr-Abl Coiled-Coil Domain Mutations Impair Oligomerization In Vivo generated a series of mutations that are predicted to disrupt the coiled-coil domain while leaving the extreme Bcr-Abl is predicted to form oligomers through the coiled-coil domain. To assess oligomerization by the N terminus of Bcr-Abl intact. p210⌬cc removes amino acids 31 to 69 and deletes the entire coiled-coil domain coiled-coil domain mutants, we generated additional constructs that were truncated at a C-terminal BstEII (Figure 1C ). p210F54P mutates phenylalanine at position 54 to proline ( Figure 1G) and is similar to a proline-con-site: p210⌬cc/⌬BX, p210F54P/⌬BX, and p210LZA/⌬BX (Figures 1D, 1H, and 1M) . The full-length and truncated taining peptide insertion mutant described previously . The F54P mutation places a constructs were coexpressed in 293T cells and immunoprecipitated with the GEX5 antibody (C) that recognizes proline in the middle of the domain and is predicted to disrupt the coiled-coil by introducing a kink to the middle only the full-length protein (Figure 2A, lane 3) . The antibody pEX2 (N) recognizes and immunoprecipitates both of the ␣ helix. The third mutant, p210LZA ( Figure 1L) , has point mutations at the "a" and "d" positions across full-length and truncated p210 proteins (Figure 2A, lane  2) . Strong coassociation of the truncated p210 protein the coiled-coil domain, with Val28, Ile31, Leu35, Ile42, Leu45, Val49, Met56, Leu59, and Leu63 changed to ala-was seen with full-length p210 (Figure 2A) whereas the truncated p210⌬cc no longer associated with the full-nine. These point mutations are predicted to conserve the helical structure of the coiled-coil but replace the length version. Likewise, coassociation of the full-length and truncated p210 proteins was lost in the presence residues essential for stabilization of the dimer structure. Similar alanine substitution mutations in the leucine zip-of either the F54P or LZA mutations. Thus, in vivo oligo- to stimulate Abl kinase activity (Brasher and Van Etten, 2000) . Surprisingly, the in vivo catalytic activity of p210 was relatively unaffected by the F54P mutation. This merization of p210 Bcr-Abl is dependent on an intact appeared to be the consequence of residual oligomeramphipathic coiled-coil domain.
ization of this mutant protein, because substitution of alanines for the "a" and "d" coiled-coil residues of p210F54P resulted in very low kinase activity (Figure 3 ,
Decreased In Vivo Tyrosine Kinase Activity of Bcr-Abl Coiled-Coil Deletion and Alanine Substitution
compare p210F54P and p210F45P/LZA). These results demonstrate that oligomerization is required for dysreg-
Mutants Is Restored by Loss of SH3 Function
We next assessed the in vivo tyrosine kinase activity of ulation of Bcr-Abl kinase activity in vivo. Previous studies demonstrated that transformation of the Bcr-Abl coiled-coil mutant proteins. We transduced interleukin-3 (IL-3)-dependent Ba/F3 hematopoietic cytokine-dependent hematopoietic cell lines by Bcr-Abl lacking amino acids 1-63 can be partially rescued by cells with BCR-ABL retroviruses, selected G418-resistant populations in the presence of IL-3, and prepared deletion of the SH3 domain (Maru et al., 1996) . To determine whether the in vivo tyrosine kinase activity of oligo-extracts after IL-3 deprivation. The Bcr-Abl coiled-coil mutant proteins were consistently expressed at levels merization-defective Bcr-Abl can be restored by loss of SH3 ligand binding function, we generated two addi-higher than wild-type p210 Bcr-Abl (Figure 3 , bottom panel), suggesting that oligomerization of Bcr-Abl may tional sets of Bcr-Abl mutants. In the first set, proline 1013 was mutated to leucine to generate p210⌬cc/ affect the stability of the protein in vivo, possibly because activated Abl proteins are more sensitive to pro-P1013L, p210F54P/P1013L, and p210LZA/P1013L (Figures 1E, 1I, and 1N ). This mutation, which corresponds teasomal degradation (Echarri and Pendergast, 2001). Despite higher Bcr-Abl levels, cells expressing p210⌬cc to P131L in type Ib/IV c-Abl, has been shown to activate c-Abl kinase and transforming activity and disrupts SH3 function by eliminating proline-rich ligand binding (Van Etten et al., 1995) . In a second set of constructs, proline 1124 was mutated to leucine to generate p210⌬cc/ P1124L, p210F54P/P1124L, and p210LZA/P1124L (Figures 1F, 1J, and 1O) . The P1124L mutation lies in the linker region between the Abl SH2 and catalytic domains at the site of intramolecular SH3 binding defined in c-Abl, and mutation of the corresponding residue (P242) to alanine or leucine has also been shown to activate the catalytic and transforming activity of type Ib/IV c-Abl (Barila and Superti-Furga, 1998; Brasher et al., 2001). Addition of either the P1013L or P1124L mutations to p210⌬cc or p210LZA increased levels of cellular phosphotyrosine to that of wild-type p210-expressing cells without grossly altering the spectrum of phosphorylated proteins (Figure 3) , but had little effect on the high constitutive activity of p210F54P. These data demonstrate that loss of SH3 ligand binding function restores maximal in vivo catalytic activity to Bcr-Abl in the absence of oligomerization.
Bcr-Abl Coiled-Coil Deletion and Alanine Substitution Mutants Are Defective for Transformation of Fibroblasts
To determine the impact of oligomerization on Bcr-Abl transforming activity, we tested the ability of the coiledcoil mutants to induce the anchorage-independent growth of fibroblasts. NIH 3T3 10 3 cells under these conditions ( Figure 5A ), while only The c-Abl kinase is activated fully following sequential adherent stromal cells were seen in cultures of untransautophosphorylation at two sites: Tyr412 in the activaduced cells ( Figure 5B ). The coiled-coil deletion or alation loop of the catalytic domain and Tyr245 in the linker nine substitution mutants were completely defective in region between the SH2 and catalytic domains (Brasher this assay, with no detectable growth even at the highest and Van Etten, 2000). Using tyrosine to phenylalanine plating density (Figures 5C and 5F ). Expression of substitution mutants, we examined the requirement for p210F54P resulted in growth of some wells at higher these sites for Bcr-Abl kinase activity and transformaplating densities, but growth of the lower dilutions was tion. Mutation of either the homologous activation loop impaired relative to wild-type p210 ( Figure 5I ), while the tyrosine (Tyr1294) or the SH2-CD linker tyrosine (Tyr1127) p210F54P/LZA double mutant was completely inactive alone modestly decreased Bcr-Abl in vivo kinase activ-( Figure 5O ). Transformation by all three coiled-coil doity, while a Y1127/1294F double mutant displayed even main mutants was significantly increased by secondary lower activity (Figure 3 ). Tyr to Phe mutation at either mutations in the SH3 or SH2-CD linker sites, particularly position was sufficient to abolish fibroblast transformaby the P1124L mutation, which restored transformation tion by Bcr-Abl ( Figure 4A ). Taken together, these results to the level of wild-type p210 in all cases. Expression of demonstrate that loss of either oligomerization or auto-p210Y1294F resulted in modestly decreased cell growth phosphorylation results in defective fibroblast transforrelative to that induced by wild-type p210 ( Figure 5M ), mation by Bcr-Abl.
while the Y1127F and Y1127/1294F mutants showed no growth at any cell plating density (Figures 5L and 5N) . Figure 6) , characterized by peripheral blood leukocytosis with greatly increased neutro-p210LZA resulted in IL-3 independent growth that was comparable to that of cells expressing wild-type p210 phils, hepatosplenomegaly, and infiltration of spleen, liver, and lungs with maturing myeloid cells (Li et al., 1999) . (Figures 4C and 4D) . As in fibroblasts, the loss of Bcr-
Figure 5. Bcr-Abl Coiled-Coil Deletion and Alanine Substitution Mutants Cannot Transform Primary Bone Marrow B-Lymphoid Progenitors
Balb/c bone marrow was transduced with the indicated BCR-ABL retrovirus and plated at indicated cell numbers per well in triplicate wells. Nontransduced cells were added to 10 6 total cells to provide stromal support. Wells were scored as positive when the viable nonadherent cell number reached 10 6 /well. Although p210Y1294F was previously reported to be defective in this assay (Pendergast et al., 1993) , this might be due to low virus titer in that study. antsev et al., 2001) . These results demonstrate that efficient oligomerization through the coiled-coil domain and with p210⌬cc or p210LZA failed to develop CML-like disease, but instead succumbed to T-lymphoid leuke-maximal levels of Bcr-Abl kinase activity are required for induction of CML. mia/lymphoma (T-ALL) after a long latent period ( Figures  6A and 6B) , characterized by thymic enlargement and The P1013L SH3 mutation rescued efficient induction of CML-like disease by p210⌬cc ( Figure 6A) Zhang et al., 2001) and implicates directly the ligand binding function of the SH3 thymus, and a hemorrhagic malignant pleural effusion that was the cause of death ( Figure 6C) . The same dis-domain in the rescue mechanism. The P1124L SH2-CD linker mutation also restored induction of CML-like ease is induced by p210 Bcr-Abl with a point mutation in the SH2 domain that impairs catalytic activity (Roumi-disease by p210⌬cc although less efficiently ( Figure 6A ).
In contrast, mice transplanted with marrow transduced

with all circulating CD4/CD8-positive cells (data not shown). Similar T-lymphoma occurs in recipients of marrow ex-recipients succumbing within 10 weeks posttransplant with leukocytosis due to maturing myeloid cells, hepato-pressing Bcr-Abl lacking the entire Bcr N terminus or with a point mutation in the Grb2 binding site at Tyr177 splenomegaly, and pulmonary infiltrates and hemorrhage. These mice had normal lymph nodes and thymus (He et al., 2002; Million and Van Etten, 2000; Zhang et al., 2001), and results from transduction of T-lymphoid and no evidence of B-or T-lymphoid malignancy based on histopathological and flow cytometric analysis (data progenitors in the donor bone marrow. Recipients of marrow transduced with p210F54P developed rapidly not shown). This result is consistent with the induction of CML-like disease by p210 with deletions in both the fatal acute B-lymphoid leukemia (B-ALL) characterized by moderate splenomegaly, lymphadenopathy, normal coiled-coil and SH3 domains (
Figure 6. Oligomerization and Autophosphorylation Are Required for Induction of CML by Bcr-Abl
Kaplan-Meier survival curve for recipients of marrow transduced with p210 Bcr-Abl and the indicated mutants. The number of individual mice in each arm is indicated. The p210 curve (solid black line) consists of 11 animals from three independent transplantation experiments. The disease phenotype of each animal is indicated by the shaded symbols. Mice that succumbed to two diseases simultaneously are indicated by the multi-shaded symbols. Significant differences in survival (Mantel-Cox test) were found between recipients of marrow transduced with p210 versus p210⌬cc (p Ͻ 0.0001), p210⌬cc versus p210⌬ccP1013L (p ϭ 0.0001), p210 versus p210LZA (p Ͻ 0.0001), p210LZA versus p210LZAP1124L (p ϭ 0.026), p210 versus p2101294F (p Ͻ 0.0001), and p210 versus p210Y1127/1294F (p ϭ 0.001).
Likewise, mutation at either Pro1013 or Pro1124 re-had myeloproliferative disease with splenomegaly and peripheral blood leukocytosis, but eventually succumbed stored induction of CML-like myeloproliferative disease by p210LZA ( Figure 6B) 
. Two recipients of p210LZA/ to T-lymphoma or HS. Together, these results argue that oligomerization of Bcr-Abl via the coiled-coil domain P1013L-transduced marrow succumbed to myeloproliferative disease but with longer latency compared to is required for induction of CML-like myeloproliferative disease in mice, but disruption of the SH3 domain ligand mice receiving either p210-or p210⌬cc/P1013L-transduced marrow, suggesting that the SH3 point mutation binding function or a complementary mutation in the intramolecular SH3 binding site can compensate for de-complements this particular coiled-coil domain mutation inefficiently, as it does for B-lymphoid transforma-fects in oligomerization.
Mutation of the homolog of the major autophosphory-tion ( Figure 5G) . The P1124L mutation rescued p210LZA more effectively, with five of seven recipients developing lation site in c-Abl significantly attenuated leukemogenesis by p210 Bcr-Abl, with the majority of recipients of CML-like disease and the remaining two animals developing T-ALL and histiocytic sarcoma (HS), another Bcr-p210Y1294F-transduced marrow developing CML-like disease but only after a significant delay ( Figure 6D ).
Abl-induced hematologic malignancy that can develop in transplant recipients after long latent periods (Li et al.,
Single mutation of the homolog of the c-Abl secondary autophosphorylation site in the SH2-CD linker (Y1127F) 1999). Interestingly, the P1013L mutation also partially rescued induction of myeloproliferative disease by had no effect on leukemogenesis, but p210 lacking both potential autophosphorylation sites (p210Y1127/1294F) p210F54P, with three of eight recipients developing typical CML-like disease and one succumbing to simultane-was severely impaired for induction of CML-like disease, with the majority of mice lacking evidence of myeloprolif-ous CML and B-ALL. The remaining mice in this cohort erative disease and developing T-lymphoma ( Figure 6D) .
unaccounted for by this model. When expressed at physiological levels, type Ia c-Abl is regulated despite These results demonstrate that two regulatory autophosphorylation sites that stimulate the catalytic activity the lack of a myristoyl group, as is a c-Abl Ib mutant lacking the myristoylation site and first 45 residues of of c-Abl by reversing an autoinhibited state are also required for efficient induction of CML by Bcr-Abl. the cap (Franz et al., 1989 ). In addition, there is evidence that c-Abl is also regulated in vivo by phosphoinositide lipids (Plattner et al., 2003) ). The precise mechanism of SH2dependent activation of Bcr-Abl is not known but has state by other means.
Taken together, these observations suggest that an been suggested to involve SH2 binding to phosphoserine residues C-terminal to the coiled-coil domain in Bcr elegant and simple mechanism governs Bcr-Abl catalytic activity (Figure 7) . Our results argue that Bcr-Abl Bcr-Abl has an autoregulated state that is similar to c-Abl, and our results provide direct proof of this hypoth-
